Literature DB >> 839069

Alternative pathway of complement: nonenzymatic, reversible transition of precursor to active properdin.

O Götze, R G Medicus, H J Müller-Eberhard.   

Abstract

A method for the purification of properdin in precursor state (pre-P) has been elaborated. Precursor properdin, in contrast to activated properdin (P), does not initiate the formation of a C3 convertase when added to properdin-depleted serum, rather it requires the presence of an activating substance such as zymosan for expression of its activity. Comparing the activities of pre-P and P it was found that some P preparations contained significant amounts of pre-P because they were fully active only in the presence of zymosan. This observation indicated that P can partly revert to pre-P. Comparison by immunoelectrophoresis and sodium dodecyl sulfate polyacrylamide gel electrophoresis revealed no charge or size differences between pre-P and P. Radiolabeled pre-P, when analyzed after its participation in the reactions of the pathway, displayed an unchanged subunit m.w. of 50,000. Taken together, these results strongly suggest that the transition of pre-P to P is due to a partly reversible change in the conformation of the protein rather than the result of proteolytic cleavage.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 839069

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.

Authors:  R D Schreiber; M K Pangburn; P H Lesavre; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

2.  Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.

Authors:  T C Farries; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1988-05-15       Impact factor: 3.857

3.  Resolution and analysis of 'native' and 'activated' properdin.

Authors:  T C Farries; J T Finch; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1987-04-15       Impact factor: 3.857

Review 4.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

5.  The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan.

Authors:  R G DiScipio
Journal:  Biochem J       Date:  1981-12-01       Impact factor: 3.857

6.  Mapping of the properdin-binding site in the third component of complement.

Authors:  J D Lambris; J Alsenz; T F Schulz; M P Dierich
Journal:  Biochem J       Date:  1984-01-01       Impact factor: 3.857

7.  Antibody-independent activation of the alternative complement pathway by measles virus-infected cells.

Authors:  J G Sissons; M B Oldstone; R D Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

8.  Properdin deficiency in a family with fulminant meningococcal infections.

Authors:  A G Sjöholm; J H Braconier; C Söderström
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

9.  The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Biochem J       Date:  1986-05-01       Impact factor: 3.857

Review 10.  Properdin: approaching four decades of research.

Authors:  K K Maves; J M Weiler
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.